Choate Investment Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Choate Investment Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-9,002	Closed	-$224K	–	229
2018 Q3	$224K	Sell	9,002 -1,258	-12%	-$30.9K	0.01%	185
2018 Q2	$248K	Buy	+10,260	New	+$277K	0.01%	207

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Choate Investment Advisors's CNCR Position: Q4 2018 in Review

Choate Investment Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2018, closing a stake of 9,002 shares — an estimated $224K sold.

Choate Investment Advisors first reported a position in CNCR in Q2 2018 and held it in 2 quarters. The position peaked at $248K in Q2 2018. 23 funds tracked by Wall St. Rank hold CNCR as of Q4 2018.

Choate Investment Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2018 after selling out during the quarter.
Choate Investment Advisors sold 9,002 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2018, an estimated $224K.
Choate Investment Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2018 and held it in 2 quarters.
Choate Investment Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $248K in Q2 2018.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2018.

Based on Choate Investment Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.